These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27502779)

  • 1. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
    Mezencev R; Švajdler M
    Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.
    Sandberg ME; Hartman M; Klevebring D; Eloranta S; Ploner A; Hall P; Czene K
    Breast Cancer Res Treat; 2012 Jul; 134(2):793-800. PubMed ID: 22622811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
    Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
    Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.
    Liu J; Jiang W; Mao K; An Y; Su F; Kim BY; Liu Q; Jacobs LK
    Breast Cancer Res Treat; 2015 Apr; 150(2):439-45. PubMed ID: 25764167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
    Brooks JD; John EM; Mellemkjaer L; Lynch CF; Knight JA; Malone KE; Reiner AS; Bernstein L; Liang X; Shore RE; Stovall M; ; Bernstein JL
    Cancer Med; 2016 Nov; 5(11):3282-3291. PubMed ID: 27700016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
    Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
    Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study.
    Sandberg ME; Hall P; Hartman M; Johansson AL; Eloranta S; Ploner A; Czene K
    PLoS One; 2012; 7(10):e46535. PubMed ID: 23056335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of contralateral second primary breast cancer according to hormone receptor status in Germany.
    Rusner C; Wolf K; Bandemer-Greulich U; Engel J; Stegmaier C; Holleczek B; Schubert-Fritschle G; Tillack A; Stang A
    Breast Cancer Res; 2014 Oct; 16(5):452. PubMed ID: 25277819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER.
    Neta G; Anderson WF; Gilbert E; Berrington A
    Breast Cancer Res Treat; 2012 Feb; 131(3):1021-7. PubMed ID: 22015617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour?
    Coradini D; Oriana S; Mariani L; Miceli R; Bresciani G; Marubini E; Di Fronzo G
    Eur J Cancer; 1998 May; 34(6):825-30. PubMed ID: 9797693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015.
    Kurian AW; Canchola AJ; Ma CS; Clarke CA; Gomez SL
    Cancer; 2020 Mar; 126(5):958-970. PubMed ID: 31750934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second primary breast cancer occurrence according to hormone receptor status.
    Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
    J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.
    Nichols HB; Berrington de González A; Lacey JV; Rosenberg PS; Anderson WF
    J Clin Oncol; 2011 Apr; 29(12):1564-9. PubMed ID: 21402610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of second breast cancer according to estrogen receptor status and family history.
    Bouchardy C; Benhamou S; Fioretta G; Verkooijen HM; Chappuis PO; Neyroud-Caspar I; Castiglione M; Vinh-Hung V; Vlastos G; Rapiti E
    Breast Cancer Res Treat; 2011 May; 127(1):233-41. PubMed ID: 20878464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
    Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
    Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype.
    Kramer I; Schaapveld M; Oldenburg HSA; Sonke GS; McCool D; van Leeuwen FE; Van de Vijver KK; Russell NS; Linn SC; Siesling S; Menke-van der Houven van Oordt CW; Schmidt MK
    J Natl Cancer Inst; 2019 Jul; 111(7):709-718. PubMed ID: 30698719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis.
    Li Z; Wu Q; Song J; Zhang Y; Zhu S; Sun S
    Horm Cancer; 2018 Jun; 9(3):197-204. PubMed ID: 29556910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race, ethnicity and risk of second primary contralateral breast cancer in the United States.
    Watt GP; John EM; Bandera EV; Malone KE; Lynch CF; Palmer JR; Knight JA; Troester MA; Bernstein JL
    Int J Cancer; 2021 Jun; 148(11):2748-2758. PubMed ID: 33544892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.